Rich McAvoy Appointed as Chief Business Officer at Avid Bioservices

Avid Bioservices Welcomes Rich McAvoy as New Chief Business Officer

Avid Bioservices, a prominent contract development and manufacturing organization (CDMO), has announced the appointment of Rich McAvoy as Chief Business Officer (CBO) as of January 16, 2026. This strategic move comes at a pivotal time as the company embarks on its next growth phase, focusing on refined operational execution and enhanced customer experience.

Rich McAvoy arrives at Avid with a wealth of industry experience, particularly in areas such as strategic investment management, operational finance, compliance, and risk management. His track record makes him an ideal fit at this phase of Avid's development, where disciplined execution and scalability are crucial for the organization.

Kenneth Bilenberg, CEO of Avid Bioservices, stated, "As Avid embarks on its next growth stage, we are keen on scaling our operations to bolster our execution and improve customer experience. Rich is known for building disciplined organizations that guarantee reliable delivery, making him the right leader for Avid. We are excited to welcome him to our team as we expand our partnerships and elevate the standards we set as a CDMO."

The appointment is particularly significant given the current dynamics in the biopharmaceutical industry, with many sponsors reevaluating their strategies to ensure supply chain resilience amid changing geopolitical uncertainties and trade barriers.

Rich expressed enthusiasm about joining Avid during a time of clear growth ambitions. He said, "Avid has built a strong reputation for quality and delivery, and I am thrilled to be part of the team at such an exciting juncture. My focus will be on rigorous execution and ensuring that we consistently deliver on time while providing an exceptional experience to our clients. Consistency in delivery and execution will set us apart in the marketplace and position us as a preferred partner."

McAvoy’s appointment strengthens Avid’s leadership team as the company continues to improve its services and forge alliances with innovative biopharmaceutical players. Avid remains dedicated to assisting its clients in advancing critical programs through reliable execution, agile collaboration, and high-quality manufacturing, adhering to current Good Manufacturing Practices (CGMP).

About Avid Bioservices

Avid Bioservices is a global CDMO specializing in mammalian cell culture manufacturing. Based in the United States, the company has an impeccable track record with the FDA, earning the trust of biopharmaceutical innovators worldwide for its agility, quality, and capacity to navigate complex global regulatory environments.
With experience supporting both emerging biotech companies and large multinational pharmaceutical firms, Avid provides comprehensive solutions from development through commercial supply.

Avid At a Glance

- Over 600 batches manufactured
- More than 275 commercial batches delivered globally
- Over 6 commercially approved products
- 10 successful pre-approval/license inspections with major regulatory agencies

Rich McAvoy’s strategic vision and leadership are expected to propel Avid Bioservices into new growth opportunities, reinforcing its reputation as a reliable partner in the biopharmaceutical landscape.